Does This Marijuana Company Have A Legal Monopoly?

'Seed To Sale' Investors Are Drooling Over The Potential
By J. Daryl Thompson

It’s 2019, marijuana is BOOMING, consumers are embracing its new products, laws are changing, and investors are pouring money into marijuana stocks...and you have a BRILLIANT idea that could make you a FORTUNE:

Own the entire marijuana process...from Seed to retail Sale.

The bad news: one company had that idea in 2014 and is already so far ahead of you that the only way to experience a potential plume of profits is to invest in that company!

csi stock

Innovation from Seed To Sale Gives Investors MAJOR Upside

In the exploding Marijuana market, the ability to control costs from cultivation to retail sales has only upside. Where most companies in the marijuana industry lose profits is here… but Chemesis is the ONE company that can actually GROW profits!

See Where You Could Invest In Chemesis HERE

Chemesis International Inc. (OTC:CADMF)(CSI:CSE) leadership knew in 2014 that the marijuana industry had already become the biggest profit center for the next 50 years. They knew companies investing in grow farms, manufacturing, global delivery, and of course the retail space, and consulted with investing firms jumping from one speculated HOT sector to the next.

What they saw, was that no one was investing in them ALL… Chemesis started creating a seed to sale strategy, garnering profit margins and cost controls to return massive profits back to investors.

Here’s How They’re Monopolizing Massive Profits

Chemesis started out researching 5 of the most profitable growth sectors of the industry, including cultivation, packaging, transportation, branding and retail, and acquired companies in these spaces who on their own were successful, but TOGETHER would create massive profitability from each, leaving no link in the supply chain broken. Four years later, Chemesis has become the ONLY, conglomerate in the market, like Costco, Nestle and Procter & Gamble.

So, How did they do it?

In Puerto Rico, Chemesis International Inc. (OTC:CADMF) (CSI:CSE) has a fully compliant, state-of-the-art facility that is 35,000 ft² and has a license to cultivate 100,000ft² of cannabis. This rivals any in the market today. Their facility in California gives Chemesis the capacity to produce 30,000+ lbs of cannabis per year and 90 kilos of crude oil/day. This production set Chemesis up to be highly competitive in what is the biggest cannabis market in the world. But, where other companies stopped at cultivation and production, Chemesis continued to aggressively pursue their business model and moved into packaging, transportation, branding and retail.

Chemesis owns Desert Zen a transportation and distribution company, that has passed California’s stringent cannabis transportation laws, and is able to track, monitor and ensure that all sale-to-seed laws are followed throughout their business vertical. Desert Zen, has even begun servicing other producers throughout the region.

At this stage, Chemesis had completed a four-year business plan that encompasses all stages of the business vertical, helping them profit at EVERY business exchange.

The last phase of their plan, rolled out in the 4th quarter of 2018. Leaving the biggest opportunity for investors to buy-in now, right before the biggest profits to date are returned to investors. AND, that’s even after their stock has increased more than 300%, since July. Chemesis International’s last phase of their initial business plan was completed this year, when they purchased an 80% interest in Natural Ventures and SAP Global. Natural Ventures is Puerto Rico’s largest seed-to-sale medicinal cannabis company. SAP Global is known for its high-quality oil-based products throughout the west coast, and has been the recipient of 26 awards in the past five years.

Chemesis Scores Market Moving Brands

Chemesis controls or has exclusive partnerships with six high recognition brands with followings in the TENS OF MILLIONS on social media. When customers shop at ANY of the multi-state retails shops, they won’t miss one of the Chemesis brands, turning those purchases into investor profits!

Learn More About Chemesis Brands HERE

Exclusive Markets

At this point most companies would have stopped spreading throughout the industry, but Chemesis has spent so much time evaluating the broader market, with their eyes set on becoming THE industry conglomerate, that they continued to see opportunity in markets where others didn’t.

These opportunities have taken them beyond California and Chemesis is now operating in Columbia and Puerto Rico.

Announced late in 2018 Chemesis came into partnership with Rapid Dose Therapeutics, a Canadian bio-technology company providing a disruptive proprietary drug delivery technology designed to improve patient outcomes, with QuickStrip™ Oral Thin Strips to Puerto Rico and California.

Prohibition Partners believes that the Latin American cannabis industry will soon grow from $125 million in revenue this year to $12.7 billion by 2028 and Chemesis is nearly their only producer. On November 5, Chemesis International Inc. (OTC:CADMF) (CSI:CSE), followed up their huge year of acquisitions in 2017, with more in 2018, entering into a binding Letter of Intent to acquire 100% of Colombia-based La Finca Interacviva-Arachna Med SAS (La Finca), an integrated cannabis company licensed and operational in Colombia since 2017.

La Finca covers over 1000 acres of outdoor cannabis cultivation and is aggressively exploring expansion opportunities throughout the country. After securing the Puerto Rican and Colombian cannabis markets Chemesis International created a subsidiary DBA Chemesis Latin America, focused on their continued expansion of Central and South America.

Marijuana Growth Just STARTING!

Diversification is what excited the markets last year, when Molson Coors announced they were partnering with Hexo Corp. to create cannabis-infused beverages. Almost immediately, Hexo’s stock jumped as much as 124%. Two weeks later, Constellation Brands pulled off their own deal, partnering with Canopy Growth Company. Constellation owns Corona, and after investing $5 billion in Canopy, their stock jumped over 133%. Tilray, who seems adamant about keeping control of their own company also skyrocketed 100% over five days, just from speculation it MIGHT be getting an investment from Coca-Cola - speculation the CEO wholeheartedly denies.

The importance of choosing the right cannabis company cannot be stressed enough; the market is starting to select its winners. The biggest to date are now household names like Aurora Cannabis and Canopy Growth. These companies are poised to be profitable in the long run because of their willingness to diversify and from their partnerships with American companies.

But, trading over 250 times earnings is a bit steep to rationalize that their stock prices are going to escalate much further, especially anytime soon. Therefore, it is essential to investigate companies that have scaled American markets for profitability. Few of these companies exist, but some are starting to shine out from the rest. Chemesis International is one such company, whose stock has risen over 500% since July. They have shadowed companies like Aurora and Canopy, striking deals with American companies in multiple markets, but have entered even more.

What Fully Compliant Distribution REALLY Means for Chemesis…

With the ability to cultivate over 30,000+lbs of product and manufacture 2,000 lbs of raw material into products and oils, Chemesis could supply the ENTIRE USA...but without the legal distribution, they’d be dead in the water. But they’ve partnered with a FULLY COMPLIANT distributor who can take their product into ANY state that can sell medicinal or recreational products produced by Chemesis. 

It means the more states that get legal, they can INSTANTLY profit from product sales because they can LEGALLY deliver!

Learn More About Chemesis's unique distribution process.

Chemesis International has been able to diversify to a greater extent than any of these companies. Their footprint in American markets is larger. They have also taken over the Puerto Rican market, Columbia and have a business vertical in America that is bigger and more robust than any other.

So why haven’t many consumers heard of them? This is because they are positioned to be a conglomerate in the industry with a well-diversified, vertically- integrated business model like Procter & Gamble or Berkshire Hathaway. Chemesis is gaining a foothold in several cannabis sectors and geographical regions, flexing their strength and buying power to become THE cannabis conglomerate of the U.S. Chemesis International has cornered five of the most highly profitable and fastest growing cannabis markets, and have the greatest potential for growth in the country.

To learn more about Chemesis International before the market could explode, visit this information page NOW.

In addition to Chemesis, you’ll want to learn more about ALL the Cannabis investment opportunities, so I’ve put together the…

The Big Book of Pot Investments


THIS REPORT/ADVERTORIAL (“ADVERTORIAL”) IS A PAID COMMERCIAL ADVERTISEMENT AND IS FOR GENERAL INFORMATION PURPOSES ONLY. Neither The Trading Letter nor Daryl Thompson (“Endorser) is making a recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by readers that learn of the profiled companies through this website. This Advertorial was paid for by a non-issuer third party in an effort to enhance public awareness of Chemesis International Inc. (OTC:CADMF)(CSE:CSI) and its securities. TheTradingLetter.com has or will receive $48,000 in cash in connection with this effort. Endorser has or will receive compensation in the form of leads valued at approximately $1,000 that are expected to result in additional subscription revenue in connection with this effort. Neither TheTradingLetter.com nor Endorser currently holds the securities of Chemesis International Inc. and do not currently intend to purchase such securities. Endorser is solely responsible for and has ultimate authority over the Advertorial and contents of the statements contained in this Advertorial. This Advertorial is based exclusively on information generally available to the public and does not contain any material, non-public information. Neither TheTradingLetter.com nor Endorser warrants the accuracy of such information. Certain statements contained in this Advertorial may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," “expects," "projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Neither TheTradingLetter.com nor Endorser undertakes an obligation to update forward-looking statements in light of new information or future events. Readers can review all public SEC filings made by the featured company at https://www.sec.gov/edgar/searchedgar/companysearch.html.

Neither TheTradingLetter.com nor Endorser are licensed in the securities industry in any manner. Please review all investment decisions with a licensed investment advisor.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.